title: Safety and tolerability of a 6-week course of oseltamivir prophylaxis for seasonal influenza in children.
abstract: In an open-label study, 49 children aged 1-12 years received oseltamivir (30-75 mg once daily depending on bodyweight) for 6 weeks for influenza prophylaxis. Seventeen participants reported 22 adverse events (AEs); in three participants, AEs were considered probably drug related (nausea or vomiting). No serious AEs were reported. The tolerability profile was similar to pooled safety data from treatment studies (duration of 5 days) in children.
authors.affiliation: Primary Physicians Research, Pittsburgh, PA, USA.
authors.forename: Keith
authors.initials: K
authors.lastname: Reisinger
authors.forename: Daniel
authors.initials: D
authors.lastname: Shu
authors.forename: Lisa
authors.initials: L
authors.lastname: Cupelli
authors.forename: Isaac
authors.initials: I
authors.lastname: Marcadis
authors.forename: Regina
authors.initials: R
authors.lastname: Dutkowski
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D018890:Chemoprevention; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007251:Influenza, Human / Q000517:prevention & control*; D008297:Male; D053139:Oseltamivir / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D012621:Seasons; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D053139:Oseltamivir